TIMESPAN
@TIMESPAN_H2020
Followers
269
Following
667
Media
167
Statuses
444
Management of chronic cardiometabolic disease and treatment discontinuity in adults with #ADHD
https://timespan.eu
Joined March 2021
What happens to women’s use of other medications when they start treatment for ADHD? Ms Dani Russell's PhD research brings together data, lived experience, and a gendered lens to understand the unique experiences of women with #ADHD. See more on the blog: https://t.co/Of8Tc1g3kn
0
0
0
New research from Iceland highlights an important link between #ADHD and #womenshealth. Using data from the Icelandic @SAGACohort, the team found that women with ADHD experience more severe, and earlier, symptoms of #perimenopause. 👉 Read more: https://t.co/VUkh8EgA38
0
0
1
@TIMESPAN_H2020 Project Update: This year, TIMESPAN published work in Lancet Psychiatry and hosted a major public event on ADHD, obesity, and long-term health across Europe. Read more: https://t.co/TKtTFrdbgx
0
1
2
🚀 Highlights from the AADPA’s 8th Annual Conference on ADHD! Our team from @hkumed presented insights on early executive function development and community partnerships for children with #ADHD. Let’s advance ADHD care together! #HealthcareInnovation #CommunityEngagement
0
0
0
📢 New @bmj_latest study: #ADHD medication is linked to reduced risks of suicide, substance misuse, transport accidents & criminality. Work led by TIMESPAN partners @karolinskainst highlights benefits beyond core symptoms. 🔗 https://t.co/VWBh3fuDac
#AdultADHD #ADHDmedication
0
0
0
💬 “Once I understood my ADHD, and once I received acceptance instead of ongoing confusion, I was able to grow into a person I never thought I could be.” For #ADHDAwarenessMonth, Christian shares his powerful story. 🎧 Listen here 👉 https://t.co/sHacKN5HJ7
#ADHD @ADHD_Europe
0
1
2
The #ADHD Remote Technology Study of Cardiometabolic Risk Factors and Medication Adherence (ART-CARMA) team discuss their preliminary findings and attendance at the #EUNETHYDIS (the European Network for ADHD) 36th annual meeting. 👏 🔗Read more: https://t.co/Pdn70vOujf
0
1
0
🎙 New TIMESPAN podcast episode! For #ADHDAwarenessMonth (The Many Faces of ADHD), we invited Viljo Wilding (@UK_ADHD, @ADHD_Europe) to talk about why lived experience must shape #ADHD research + what science means for real lives. 👉 Listen: https://t.co/8oDZXuCBeV
#TIMESPAN
0
0
1
🌍More data, more power, more complexity😎 Kenneth Man & Anton Pottegård share 10 field-tested tips for running multi-country pharmacoepidemiology studies that stay credible, comparable & coordinated. Read the playbook👉 https://t.co/1Bj5wCNv5I
#RealWorldEvidence #Epidemiology
0
0
3
#PCOS is more than a reproductive disorder. 💡 Our latest blog explores how PCOS links to ADHD and cardiometabolic health. And why holistic care matters. 👉 Read the full post: https://t.co/0n771ulcjx
#ADHD #CardiometabolicHealth #WomensHealth
0
0
0
Excited to share team @VHIR_'s latest research addressing the question how polygenic risk for psychiatric disorders can show up in children’s behaviors & emotions. 👧🧬 Congrats @silvialemany et al! 🔓 https://t.co/nRZibvYkwU
#MentalHealth #ChildPsychiatry
0
1
1
👏 Huge congratulations to our partner @lehto_kelli (Univ. of Tartu) on winning an ERC grant for Attention on Inattention: Dissecting the causal mechanisms of adult ADHD features! The project will aims to advance #adultADHD diagnosis. 🎉 #ERC
Great news! Our Associate Professor of Neuropsychiatric Genomics, Kelli Lehto, has been selected to receive the European Research Council grant! 💐Congrats on that outstanding achievement! 👉 https://t.co/oVmN9UgXvn
0
0
2
@TIMESPAN_H2020 project results and key findings. Higher ADHD genetic risk was linked to an increased risk of conditions like heart failure, vascular disease, obesity, type 1 diabetes, rheumatoid arthritis, and migraines. Learn more: https://t.co/cofnzgpEGO
0
1
2
TIMESPAN member @StephenFaraone (@SUNY) was recently interviewed by @DIEZEIT on ADHD. 🔗 Read our summary here: https://t.co/UsIYyGBDQx 🔗 Read the full article by DIE ZEIT here (paywalled, German only): https://t.co/0qss88XauS
#ADHD #Neuroscience
0
0
1
At our TIMESPAN forum in London (with ADDISS & ADHD-Europe), we explored why so many with #ADHD stop their medication from both #research and lived experience perspectives. Here’s what participants told us 👇 #PatientEngagement #TIMESPAN #Neurodiversity #MentalHealthResearch
0
0
1
ADHD & Cardiometabolic Disease: What’s the connection? In this week’s blog, @EASOobesity shares how TIMESPAN explores the overlap between #ADHD, #obesity & diabetes 👉 Read more: https://t.co/mVOoeBafjN
#Type2Diabetes
0
1
1
What does grassroots dissemination look like? TIMESPAN works closely with people with lived experiences & organisations to make research matter. Beyond papers and conferences. Read about our approach: 🔗 https://t.co/Pw0CikCabG
#ADHD #TIMESPAN #Scicomm
0
0
1
Understanding how people with ADHD and their caregivers seek information is key to improving health communication. @TIMESPAN_H2020 project invites you to take a short, anonymous survey (2 mins) to share your experience. https://t.co/PmCah3KPXZ
0
1
3
On #WorldBrainDay, we spotlight #ADHD, a brain condition with lifelong impact. TIMESPAN research reveals how it shapes risks for #obesity, #diabetes & heart disease. More results coming soon. @UK_ADHD @ADHD_Europe @EASOobesity
#WBD2025
0
0
0
⌚What is the value of using digital endpoints in cardiometabolic disease monitoring? Read this blog post by @empatica to understand some of their benefits, including personalized and immediate treatment, and supporting diverse populations. ➡️ https://t.co/qgRtyv7WdV
0
2
1